Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 102 entries
Sorted by: Best Match Show Resources per page
Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?.

BMJ open gastroenterology

Kaspar MB, Sterling RK.
PMID: 26966552
BMJ Open Gastroenterol. 2016 Mar 02;3(1):e000072. doi: 10.1136/bmjgast-2015-000072. eCollection 2016.

OBJECTIVE: Hyperbilirubinaemia (HB) is common in HIV and hepatitis C virus (HIV-HCV) co-infected patients and poses a unique challenge in management as it may be due to medications such as the protease inhibitors (PIs) or to hepatic dysfunction. There...

Cite
Kaspar MB, Sterling RK. Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ Open Gastroenterol. 2016;3(1):e000072doi: 10.1136/bmjgast-2015-000072.
Kaspar, M. B., & Sterling, R. K. (2016). Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ open gastroenterology, 3(1), e000072. https://doi.org/10.1136/bmjgast-2015-000072
Kaspar, Matthew B, and Sterling, Richard K. "Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?." BMJ open gastroenterology vol. 3,1 (2016): e000072. doi: https://doi.org/10.1136/bmjgast-2015-000072
Kaspar MB, Sterling RK. Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?. BMJ Open Gastroenterol. 2016 Mar 02;3(1):e000072. doi: 10.1136/bmjgast-2015-000072. eCollection 2016. PMID: 26966552; PMCID: PMC4780040.
Copy Download .nbib Format: NLM
A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

AIDS research and therapy

Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, Baer R, Sevastos J, Abbas R, Boyd MA.
PMID: 25745499
AIDS Res Ther. 2014 Nov 10;11:35. doi: 10.1186/1742-6405-11-35. eCollection 2014.

A number of antiviral agents used against Human Immunodeficiency Virus (HIV) infection and hepatitis B virus (HBV) mono or co-infection have been associated with real nephrotoxicity (including tenofovir disoproxil fumarate (TDF), atazanavir, indinavir and lopinavir) or apparent changes in...

Cite
Holt SG, Gracey DM, Levy MT, et al. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Res Ther. 2014;11:35doi: 10.1186/1742-6405-11-35.
Holt, S. G., Gracey, D. M., Levy, M. T., Mudge, D. W., Irish, A. B., Walker, R. G., Baer, R., Sevastos, J., Abbas, R., & Boyd, M. A. (2014). A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS research and therapy, 1135. https://doi.org/10.1186/1742-6405-11-35
Holt, Stephen G, et al. "A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection." AIDS research and therapy vol. 11 (2014): 35. doi: https://doi.org/10.1186/1742-6405-11-35
Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, Baer R, Sevastos J, Abbas R, Boyd MA. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Res Ther. 2014 Nov 10;11:35. doi: 10.1186/1742-6405-11-35. eCollection 2014. PMID: 25745499; PMCID: PMC4350301.
Copy Download .nbib Format: NLM
Role of pharmacokinetics in the discovery and development of indinavir.

Advanced drug delivery reviews

Lin JH.
PMID: 10837766
Adv Drug Deliv Rev. 1999 Oct 18;39(1):33-49. doi: 10.1016/s0169-409x(99)00018-6.

The discovery of indinavir is a successful example in which pharmacokinetic and metabolic information were incorporated into drug design. The use of animal and in vitro human metabolic data in predicting the oral bioavailability and hepatic clearance in humans...

Cite
Lin JH. Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Deliv Rev. 1999;39(1):33-49doi: 10.1016/s0169-409x(99)00018-6.
Lin, J. H. (1999). Role of pharmacokinetics in the discovery and development of indinavir. Advanced drug delivery reviews, 39(1), 33-49. https://doi.org/10.1016/s0169-409x(99)00018-6
Lin. "Role of pharmacokinetics in the discovery and development of indinavir." Advanced drug delivery reviews vol. 39,1 (1999): 33-49. doi: https://doi.org/10.1016/s0169-409x(99)00018-6
Lin JH. Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Deliv Rev. 1999 Oct 18;39(1):33-49. doi: 10.1016/s0169-409x(99)00018-6. PMID: 10837766.
Copy Download .nbib Format: NLM
P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs.

Advanced drug delivery reviews

Aungst BJ.
PMID: 10837770
Adv Drug Deliv Rev. 1999 Oct 18;39(1):105-116. doi: 10.1016/s0169-409x(99)00022-8.

Orally administered anti-HIV drugs must be adequately and consistently absorbed for therapy to be successful. This review discusses the barriers to achieving oral bioavailability for the currently available anti-HIV drugs. Most reverse transcriptase inhibitors have good oral bioavailabilities. Didanosine...

Cite
Aungst BJ. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev. 1999;39(1):105-116doi: 10.1016/s0169-409x(99)00022-8.
Aungst, B. J. (1999). P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Advanced drug delivery reviews, 39(1), 105-116. https://doi.org/10.1016/s0169-409x(99)00022-8
Aungst. "P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs." Advanced drug delivery reviews vol. 39,1 (1999): 105-116. doi: https://doi.org/10.1016/s0169-409x(99)00022-8
Aungst BJ. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev. 1999 Oct 18;39(1):105-116. doi: 10.1016/s0169-409x(99)00022-8. PMID: 10837770.
Copy Download .nbib Format: NLM
Human immunodeficiency virus protease inhibitors. From drug design to clinical studies.

Advanced drug delivery reviews

Lin JH.
PMID: 10837559
Adv Drug Deliv Rev. 1997 Sep 15;27(2):215-233. doi: 10.1016/s0169-409x(97)00044-6.

The discovery of human immunodeficiency virus (HIV) protease inhibitors is an example in which pharmacokinetic evaluation was implemented early in the discovery phase to obtain optimal pharmacological and pharmacokinetic properties. Currently, three HIV protease inhibitors, saquinavir, indinavir and ritonavir...

Cite
Lin JH. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv Drug Deliv Rev. 1997;27(2):215-233doi: 10.1016/s0169-409x(97)00044-6.
Lin, J. H. (1997). Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Advanced drug delivery reviews, 27(2), 215-233. https://doi.org/10.1016/s0169-409x(97)00044-6
Lin. "Human immunodeficiency virus protease inhibitors. From drug design to clinical studies." Advanced drug delivery reviews vol. 27,2 (1997): 215-233. doi: https://doi.org/10.1016/s0169-409x(97)00044-6
Lin JH. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv Drug Deliv Rev. 1997 Sep 15;27(2):215-233. doi: 10.1016/s0169-409x(97)00044-6. PMID: 10837559.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Drug-induced urolithiasis.

Current opinion in urology

Hess B.
PMID: 17038978
Curr Opin Urol. 1998 Jul;8(4):331-4.

Drugs can cause renal stone formation either by raising excretion rates of naturally occurring stone components or by directly precipitating within the urinary tract. In large series of analysed renal stones, the overall frequency of drug-induced urolithiasis is less...

Cite
Hess B. Drug-induced urolithiasis. Curr Opin Urol. 1998;8(4):331-4
Hess, B. (1998). Drug-induced urolithiasis. Current opinion in urology, 8(4), 331-4.
Hess, B. "Drug-induced urolithiasis." Current opinion in urology vol. 8,4 (1998): 331-4.
Hess B. Drug-induced urolithiasis. Curr Opin Urol. 1998 Jul;8(4):331-4. PMID: 17038978.
Copy Download .nbib Format: NLM
Herb-drug interactions: focus on pharmacokinetics.

CNS spectrums

Cott JM.
PMID: 15334037
CNS Spectr. 2001 Oct;6(10):827-32. doi: 10.1017/s1092852900001644.

Recent literature regarding drug-drug, herb-drug, and food-drug interactions must not be ignored; nor can they always be taken at face value. Studies have shown that St. John's wort (SJW) (Hypericum perforatum) can reduce plasma levels of indinavir, cyclosporin, digoxin,...

Cite
Cott JM. Herb-drug interactions: focus on pharmacokinetics. CNS Spectr. 2001;6(10):827-32doi: 10.1017/s1092852900001644.
Cott, J. M. (2001). Herb-drug interactions: focus on pharmacokinetics. CNS spectrums, 6(10), 827-32. https://doi.org/10.1017/s1092852900001644
Cott, J M. "Herb-drug interactions: focus on pharmacokinetics." CNS spectrums vol. 6,10 (2001): 827-32. doi: https://doi.org/10.1017/s1092852900001644
Cott JM. Herb-drug interactions: focus on pharmacokinetics. CNS Spectr. 2001 Oct;6(10):827-32. doi: 10.1017/s1092852900001644. PMID: 15334037.
Copy Download .nbib Format: NLM
Efavirenz: shifting the HAART paradigm in adult HIV-1 infection.

Expert opinion on investigational drugs

Moyle GJ.
PMID: 15992093
Expert Opin Investig Drugs. 1999 Apr;8(4):473-86. doi: 10.1517/13543784.8.4.473.

Efavirenz (DMP-266, Sustiva, Stocrin) is a member of the non-nucleoside class of HIV-1 reverse transcriptase inhibitors. It has demonstrated potent antiretroviral activity in treatment-naïve patients in combination with two nucleoside analogues or with a protease inhibitor. In nucleoside analogue-experienced...

Cite
Moyle GJ. Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. Expert Opin Investig Drugs. 1999;8(4):473-86doi: 10.1517/13543784.8.4.473.
Moyle, G. J. (1999). Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. Expert opinion on investigational drugs, 8(4), 473-86. https://doi.org/10.1517/13543784.8.4.473
Moyle, G J. "Efavirenz: shifting the HAART paradigm in adult HIV-1 infection." Expert opinion on investigational drugs vol. 8,4 (1999): 473-86. doi: https://doi.org/10.1517/13543784.8.4.473
Moyle GJ. Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. Expert Opin Investig Drugs. 1999 Apr;8(4):473-86. doi: 10.1517/13543784.8.4.473. PMID: 15992093.
Copy Download .nbib Format: NLM
Efavirenz DuPont Pharmaceuticals Co.

IDrugs : the investigational drugs journal

Dong BJ.
PMID: 18465625
IDrugs. 1998 Oct;1(6):700-11.

Efavirenz is the lead compound of a series of benzoxazinones originally developed by DuPont Merck. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for the potential treatment of viral infections, including HIV. In June 1998, the company...

Cite
Dong BJ. Efavirenz DuPont Pharmaceuticals Co. IDrugs. 1998;1(6):700-11
Dong, B. J. (1998). Efavirenz DuPont Pharmaceuticals Co. IDrugs : the investigational drugs journal, 1(6), 700-11.
Dong, B J. "Efavirenz DuPont Pharmaceuticals Co." IDrugs : the investigational drugs journal vol. 1,6 (1998): 700-11.
Dong BJ. Efavirenz DuPont Pharmaceuticals Co. IDrugs. 1998 Oct;1(6):700-11. PMID: 18465625.
Copy Download .nbib Format: NLM
Indinavir-induced diabetes mellitus.

Annals of Saudi medicine

Alsoub H.
PMID: 17344684
Ann Saudi Med. 1998 Jul-Aug;18(4):333-4. doi: 10.5144/0256-4947.1998.333.

No abstract available.

Cite
Alsoub H. Indinavir-induced diabetes mellitus. Ann Saudi Med. 1998;18(4):333-4doi: 10.5144/0256-4947.1998.333.
Alsoub, H. (1998). Indinavir-induced diabetes mellitus. Annals of Saudi medicine, 18(4), 333-4. https://doi.org/10.5144/0256-4947.1998.333
Alsoub, H. "Indinavir-induced diabetes mellitus." Annals of Saudi medicine vol. 18,4 (1998): 333-4. doi: https://doi.org/10.5144/0256-4947.1998.333
Alsoub H. Indinavir-induced diabetes mellitus. Ann Saudi Med. 1998 Jul-Aug;18(4):333-4. doi: 10.5144/0256-4947.1998.333. PMID: 17344684.
Copy Download .nbib Format: NLM
Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women.

Clinical drug investigation

Frost CE, Adams J, Shelton M, Ebid AH, Gugino LJ, Hewitt R, Difrancesco R, Ingalls E, Cousins S, Hu J, Morse GD.
PMID: 23315400
Clin Drug Investig. 2002;22(2):125-34. doi: 10.2165/00044011-200222020-00007.

OBJECTIVE: To characterise the pharmacokinetics of indinavir during different phases of the menstrual cycle in HIV-infected women.DESIGN: Open-label study.SETTING: The immunodeficiency clinic at Erie County Medical Center, Buffalo, New York.PATIENTS: Ten HIV-infected women were enrolled in the study. Eligibility...

Cite
Frost CE, Adams J, Shelton M, et al. Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women. Clin Drug Investig. 2002;22(2):125-34doi: 10.2165/00044011-200222020-00007.
Frost, C. E., Adams, J., Shelton, M., Ebid, A. H., Gugino, L. J., Hewitt, R., Difrancesco, R., Ingalls, E., Cousins, S., Hu, J., & Morse, G. D. (2002). Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women. Clinical drug investigation, 22(2), 125-34. https://doi.org/10.2165/00044011-200222020-00007
Frost, Charles E, et al. "Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women." Clinical drug investigation vol. 22,2 (2002): 125-34. doi: https://doi.org/10.2165/00044011-200222020-00007
Frost CE, Adams J, Shelton M, Ebid AH, Gugino LJ, Hewitt R, Difrancesco R, Ingalls E, Cousins S, Hu J, Morse GD. Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women. Clin Drug Investig. 2002;22(2):125-34. doi: 10.2165/00044011-200222020-00007. PMID: 23315400.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 102 entries